Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal of Deep Neuromuscular Blockade
NCT00379613Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2003
- Primary completion
- Jul 2004
01
Overview
Phase 2, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (4 arms), sponsored by Merck & Co. Primary endpoint: Time from start administration of sugammadex to recovery T4/T1 ratio to 0.9. Started Nov 2003; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00379613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379613.